tirzepatida glp 1 compounded glp-1 vs tirzepatide Tirzepatide Vs GLP-1 Fridays | GLP-1 Telehealth |

8 Based on data from the MAESTRO-NASH trial, resmetirom demonstrated histological benefits with a number needed to treat of five for the resolution of MASH and 8.5 for fibrosis regression, 9 thus posing significant economic challenges

Studies and real-world use suggest that the injectable formulation can offer a more predictable and manageable side effect profile for most patients

Pregnancy and breastfeeding: Tirzepatide is contraindicated for those planning pregnancies within the next 3 months, pregnant individuals, breastfeeding mothers, or mothers who have delivered a baby within the last 6 months

Emerging research suggests that GLP-1 receptor agonists may influence food preferences and reward-related eating behaviour